Powered by the world’s leading scientists
- All Scientists
- Joe Arndt
- Moore Arnold
- Bekim Bajrami
- Linda Burkly
- Thierry Bussiere
- Ellen Cahir-Mcfarland
- Thomas Cameron
- John Carulli
- Janaky Coomaraswamy
- Mark Cosentino
- Olivier Danos
- Nathan Donelson
- Anthone Dunah
- Chris Ehrenfels
- Istvan Enyedy
- Agnès Gardet
- Davide Gianni
- Jaya Goyal
- Stefan Hamann
- Chris Henderson
- Xiaoping Hronowski
- Ron Huang
- Peter Juhasz
- Mark Kankel
- Maria Lalioti
- Doug Larigan
- Kejie Li
- Edward Lin
- John Lydeard
- Jeffrey Martin
- Alexander McCampbell
- Amy McCurley
- Sha Mi
- Alvydas Mikulskis
- Michaël Mingueneau
- Sarav Narayanan
- Karel Otero-Gutierrez
- Robert Blake Pepinsky
- Rob Peters
- Martin Preyer
- Dania Rabah
- Richard Ransohoff
- Shuyu Ren
- Mia Rushe
- Sarah Ryan
- Anindya Sen
- Chase Shen
- Laura Silvian
- Benjamin Smith
- John Staropoli
- Christopher Stebbins
- Lauren Stevenson
- Meena Subramanyam
- Chao Sun
- Sai Thankamony
- Kien Trinh
- Antonio Valencia
- Qin Wang
- Dong Wei
- Ru Wei
- Andreas Weihofen
- Paul Weinreb
- Brian Wipke
- Guangqing Xiao
- Zhili Xin
The overall goal of my lab is to investigate targets and pathways implicated or hypothesized to be important in the pathogenesis and continued progression of progressive multiple sclerosis (MS), with some natural overlap in other neurodegenerative diseases. Our work includes both discovery research in specific neuroinflammatory and neurodegenerative pathways, and the related development and application of new disease models for specific aspects of progressive MS and neurodegenerative disorders. We utilize both in vivo and in vitro methodologies in our research and actively collaborate with top-tier academic labs that share similar interests. We also support a number of ongoing remyelination and neuroprotection projects at Biogen.
Prior to joining Biogen, I worked at the confluence of immunology and neuroinflammation at Elan Pharmaceuticals, where I contributed at the bench and as an in vivo pharmacology group leader for over eight years. During that time, I led research project teams and external collaborations for several MS early-discovery targets, investigated the preclinical pharmacology and mechanism of action for anti-VLA-4 antibody TYSABRI® (natalizumab), and established a number of in-house autoimmune models for MS, inflammatory bowel disease and rheumatoid arthritis to validate new targets and support small molecules in development. My earlier graduate research was conducted in the laboratory of Prof. Mike Bevan at University of Washington in Seattle, and my postdoctoral training was in the lab of Prof. Paul Allen at Washington University in St. Louis.
- Postdoctoral Fellow, Laboratory of Paul M. Allen, Ph.D., Department of Pathology and Immunology, Washington University, St. Louis, MO, 2003
- Ph.D., Immunology, Laboratory of Michael J. Bevan, Ph.D. F.R.S., Department of Immunology, University of Washington, Seattle, WA, 1997
- Orally available and efficacious α4β1/α4β7 integrin inhibitors.
Bioorg Med Chem Lett. 2013 Aug 1;23(15):4370-3. doi: 10.1016/j.bmcl.2013.05.076. Epub 2013 May 31.
Xu YZ, Smith JL, Semko CM, Rossiter KI, Fukuda JY, Dappen MS, Quincy DA, Konradi AW, Mao W, Welch B, Dreyer ML, Samant B, Zhang H, Lugar J, Liao Z, Henschel C, Petersen E, Vandevert C, Shoemaker M, Wehner N, Mutter L, Shopp G, Krimm M, Chen L, Wipke B, Dofiles L, Gallager I, Sauer JM, Messersmith EK, Pleiss MA, Bard F, Yednock TA.
- PEG conjugates of potent α4 integrin inhibitors, maintaining sustained levels and bioactivity in vivo, following subcutaneous administration.
Bioorg Med Chem Lett. 2013 Jul 15;23(14):4117-9. doi: 10.1016/j.bmcl.2013.05.048. Epub 2013 May 24.
Smith JL, Rossiter KI, Semko CM, Xu YZ, Quincy DA, Jagodzinski J, Dappen MS, Konradi AW, Vandevert C, Garrido C, Mao W, San Pablo FB, Wipke B, Dofiles L, Wadsworth A, Peterson E, Lorenzana C, Simmonds S, Messersmith EK, Bard F, Pleiss MA, Yednock TA.
- Arylsulfonamide pyrimidines as VLA-4 antagonists.
Bioorg Med Chem Lett. 2013 May 15;23(10):3070-4. doi: 10.1016/j.bmcl.2013.03.010. Epub 2013 Mar 15.
Xu YZ, Konradi AW, Bard F, Dappen M, Dofiles L, Dreyer M, Gallager I, Garrido C, Krimm M, Liao Z, Messersmith E, Mutter L, Pleiss MA, Samant B, Semko CM, Smith J, Stappenbeck F, Stupi B, Vandervert C, Welch B, Wipke B, Yednock T.
- Connexin 43 gap junction proteins are up-regulated in remyelinating spinal cord.
J Neurosci Res. 2007 Apr;85(5):945-53.
Roscoe WA, Messersmith E, Meyer-Franke A, Wipke B, Karlik SJ.
- Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes.
J Immunol. 2004 Jun 15;172(12):7694-702.
Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM.
- Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells.
J Exp Med. 2004 Feb 2;199(3):323-35. Epub 2004 Jan 26.
Shih FF, Mandik-Nayak L, Wipke BT, Allen PM.
- Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node.
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14368-73. Epub 2002 Oct 21.
Mandik-Nayak L, Wipke BT, Shih FF, Unanue ER, Allen PM.
- Dynamic visualization of a joint-specific autoimmune response through positron emission tomography.
Nat Immunol. 2002 Apr;3(4):366-72. Epub 2002 Mar 18.
Wipke BT, Wang Z, Kim J, McCarthy TJ, Allen PM.
- Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis.
J Immunol. 2001 Aug 1;167(3):1601-8.
Wipke BT, Allen PM.
- Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
Eur J Immunol. 1997 Oct;27(10):2541-8.
Buckner FS, Wipke BT, Van Voorhis WC.
- Variable binding affinities of listeriolysin O peptides for the H-2Kd class I molecule.
Eur J Immunol. 1993 Aug;23(8):2005-10.
Wipke BT, Jameson SC, Bevan MJ, Pamer EG.